Pluri (PLUR) Cash from Operations Growth (1y) (2011 - 2025)
Pluri (PLUR) Cash from Operations Growth (1y) (2011 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Pluri |
21.85 Mn |
22.34 Mn |
86,000.00 |
-12.47% |
| Date | Value |
|---|
| Dec 31, 2025 |
-12.47% |
| Sep 30, 2025 |
-33.56% |
| Jun 30, 2025 |
-20.94% |
| Mar 31, 2025 |
-2.40% |
| Dec 31, 2024 |
-26.83% |
| Sep 30, 2024 |
30.61% |
| Jun 30, 2024 |
-48.88% |
| Mar 31, 2024 |
30.79% |
| Dec 31, 2023 |
41.89% |
| Sep 30, 2023 |
23.03% |
| Jun 30, 2023 |
65.62% |
| Mar 31, 2023 |
35.57% |
| Dec 31, 2022 |
36.33% |
| Sep 30, 2022 |
13.43% |
| Jun 30, 2022 |
12.19% |
| Mar 31, 2022 |
-28.56% |
| Dec 31, 2021 |
-25.76% |
| Sep 30, 2021 |
-43.12% |
| Jun 30, 2021 |
-51.80% |
| Mar 31, 2021 |
-12.67% |
